

## Special Issue

# Drug Development and Repositioning Methodology on COVID-19

### Message from the Guest Editors

Currently, a plethora of biomedical information is available concerning COVID-19. In this context, health professionals have been challenged with finding new insights into the mechanisms underlying actions, targets, and drugs. In particular, “drug-repurposing” is an efficient methodology that generates new therapeutics for approved drugs, but not new chemical compounds. Drug repurposing relies on data-driven approaches, such as bioinformatics, cheminformatics, and system biology, suggesting that integrated network pharmacology can elucidate the signaling pathways (mechanisms), targets, and compounds. These three components could result in a potential candidate to alleviate COVID-19. The submission of original articles, reviews, and hypotheses is welcome. Topics of interest for this issue include, but are not limited to:

- The protein–protein interaction networks in COVID-19;
- The relationship among signaling-pathways–targets–compounds in COVID-19;
- Network pharmacology-based investigation into COVID-19;
- COVID-19 and drug treatments, either dry-based or wet-based experiment.

---

### Guest Editors

Dr. Ki Kwang Oh

Department of Bio-Health Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Korea

Dr. Md Adnan

Department of Bio-Health Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea

---

### Deadline for manuscript submissions

closed (31 July 2023)



## Current Issues in Molecular Biology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/114772](https://mdpi.com/si/114772)

*Current Issues in Molecular Biology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cimb@mdpi.com](mailto:cimb@mdpi.com)

[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)





# Current Issues in Molecular Biology

an Open Access Journal  
by MDPI

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,  
Christchurch 8140, New Zealand

---

#### Author Benefits

##### High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

##### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.